Trial to Test Precision Medicines for ARDS

UC San Francisco launches the PANTHER trial on Nov. 19, 2026, testing targeted drugs for acute respiratory distress syndrome.

Updated on Nov. 17, 2026 in Asthma

Bold vector editorial illustration of two sample tubes, one crimson and one amber, in a white rack on a clean bench, suggesting biomarker-based sorting.
UC San Francisco will begin the PANTHER trial on Nov. 19, 2026, testing precision drugs matched to blood biomarkers in 300 patients with acute respiratory distress syndrome. AI Illustration. Upload story photo >

UC San Francisco will begin a clinical trial on Nov. 19, 2026, testing precision medicines for acute respiratory distress syndrome (ARDS). The PANTHER trial plans to enroll 300 patients at U.S. sites and will also run abroad.

Why it matters

ARDS affects 1 in 10 patients in intensive care units and is fatal for 35% to 45% of those affected, while current treatment is largely supportive care. The trial aims to match treatments to the biological form of the disorder, after earlier research found some treatments that helped one form showed no benefit when both were analyzed together.

The PANTHER trial enrolls 300 patients at 10 U.S. institutions, with one-third assigned to usual care only, and measures days alive without major life support over the first 28 days. Whether the trial's drugs will improve outcomes in either ARDS form remains unknown until results are reported.

The players

UC San Francisco

The University of California, San Francisco is a public research university and medical center based in San Francisco, California, known for its major clinical research programs.

U.S. Department of Defense

The Department of Defense is the federal agency responsible for the U.S. military, and it is funding the PANTHER trial.

The details

Patients receive a blood test for biomarkers that classify them as having hyperinflammatory or hypo-inflammatory ARDS, and are then assigned to treatment. The trial is funded by the U.S. Department of Defense and is designed as an adaptive platform, so promising new drugs can be added and ineffective ones dropped as evidence accumulates.

Timeline

  1. Nov. 19, 2026: Clinical trial begins at UC San Francisco.

  2. Over the first 28 days: The trial measures days patients live without major life support.

Big Picture

The PANTHER trial applies a biomarker-based classification to ARDS, moving away from one-size-fits-all supportive care toward subtype-specific drug testing. Its adaptive design, which adds promising drugs and drops ineffective ones, follows the platform model used in recent multi-arm trials.

For patients with ARDS, the trial offers access to drugs matched to their biomarker-defined form rather than only supportive care, though participation is limited to enrolled sites. Patients and families should discuss with their clinicians whether trial enrollment is an option during an ARDS hospitalization.

The takeaway

Precision matching of treatments to biological subtypes may be necessary before new ARDS drugs show a benefit. The PANTHER trial's design tests that idea directly across 300 patients.

Further reading

Explore more on Asthma for respiratory conditions and related research.

Source note: This article includes information reported by Home.